Blood-Based ScoresReferral / Risk Stratification
Laboratory-Based Biomarkers • Blood-Based Scores

Fibrosis-4 Index (FIB-4)

Guideline-recommended first-line nonproprietary blood score combining age, AST, ALT, and platelet count to estimate advanced liver fibrosis risk.

What This Means for Patients

FIB-4 is the single most practical number you can calculate right from your routine lab results (CMP + CBC). One important detail for older adults: because age is multiplied on the top of the fraction, FIB-4 naturally creeps upward as we get older. In people 65 and up, studies propose raising the low-risk cutoff from 1.3 to 2.0 so you don't get false alarms based on birthday candles alone — while in people under 35, FIB-4 can under-call risk and shouldn't be trusted by itself if metabolic risk is high.

What Is FIB-4?

  • A nonproprietary score using age, AST, ALT, and platelet count1,2
  • Estimates the likelihood of advanced liver fibrosis (≥F3) in patients with suspected liver disease1,2

Use in MASLD/MASH Care

  • FIB-4 is strongly recommended by current guidelines as a risk stratification tool in primary care to identify patients suitable for ongoing monitoring versus those needing specialist referral2,5-7

How Is It Measured?

FIB-4 = Age (years) × AST (U/L) Platelet count (109/L) × √ ALT (U/L) 
  • FIB-4 is calculated using the formula below2
  • FIB-4 calculation is also offered at a nominal cost at many laboratories2,3

Strengths

  • Accessible, guideline-endorsed1,2,5-7
  • Calculators are widely available and built into some EMRs1
  • Supports identification of patients with elevated risk who should be referred and/or further evaluated to stage liver fibrosis5

Limitations

  • Age <18 years (Pediatric): strictly contraindicated — Age in the numerator causes severe false-negative scores in children and adolescents9
  • Age ≥65 years: reduced specificity (apply a higher <2.0 FIB-4 low-risk cutoff)4,5
  • Age <35 years: reduced accuracy5
    • Secondary assessment recommended in patients <35 years old with higher metabolic risk or elevated liver enzymes5
  • FIB-4 <1.3 may miss 20%–30% of biopsy-proven F2–F3 MASH in Type 2 diabetes8
Pediatric Contraindication (NASPGHAN & AAP): Never Use FIB-4 Under Age 18. Because Age sits in the numerator of the FIB-4 equation, children and adolescents with biopsy-proven bridging fibrosis or cirrhosis routinely generate falsely reassuring FIB-4 scores (<0.5).9 For youth ages 9–17 with obesity or metabolic risk, screen using sex-specific ALT thresholds (≥50 U/L boys, ≥44 U/L girls) and pediatric hepatology / elastography assessment.

Interactive FIB-4 Index Calculator

100% Private • Runs in Browser

Enter values from a recent Comprehensive Metabolic Panel (AST, ALT) and Complete Blood Count (Platelets). Built-in guardrails enforce pediatric contraindications (<18 y) and AASLD/EASL age-adjusted thresholds (≥65 y).

Proposed Age Range–Specific Cutoffs for FIB-44,5

Age Group Absence of Advanced Fibrosis Further Investigation (Indeterminate) Advanced Fibrosis (≥F3) Likely
<18 y (Pediatric) Contraindicated — use sex-specific ALT (≥50 U/L boys, ≥44 U/L girls) + pediatric imaging9
18–34 y (Young Adult) Reduced sensitivity due to young age; if T2D, obesity, or elevated ALT is present, consider SAFE score or elastography directly5
35–64 y <1.3 1.3–2.67 >2.67
≥65 y <2.0 2.0–2.67 >2.67
Type 2 Diabetes Caveat: In high-prevalence T2D or obesity clinics, up to 20%–30% of patients with biopsy-proven F2 “at-risk” MASH have a FIB-4 <1.3.8 When multiple cardiometabolic risks or persistent transaminase elevations coexist, pairing FIB-4 with the SAFE score or VCTE elastography prevents missed moderate fibrosis.